AddLife AB (publ) (ALIF_B) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and welcome to the AdLife first quarter presentation. Christina and I will take you through the numbers and the highlights of the quarter today. Then we will open up for a Q&A, as always. And then, as a reminder, I would like to ask you to stay on after the Q&A as well, because, as usual, we have a very interesting video of one of our portfolio companies, Holmen Halby, that we will be able to show you. So now let's dig into the highlights of the first quarter. So the companies within AdLife had a great start to 2025. We saw significant EBITDA margin improvements in both business areas and this is, as you probably remember, our highest priority. In lab tech, we achieved 12.1% EBITDA margin. That's a solid improvement over previous year. And in med tech, 13.5%. Almost two percentage points improvement over last year. So very strong development there. As we talk about the revenue development, that was healthy across the board in all geographies and countries. We saw slight weakness in the UK, but that was really due to a very big instrument order in the previous year. And in general, we are overseeing our product portfolio, removing some products that are less profitable, again, in alignment with our prioritization. We are driving a number of profitability improvement initiatives in a couple of companies. We see significant improvements happening there in those specific companies, but also, of course, in line with our business model of continuous improvement in all the subsidiaries. The operating cash flow is normally a bit slow in Q1 after a seasonally strong Q4. That was the case for us this year as well. However, the first quarter cash flow was significantly stronger than the corresponding quarter of last year. So great improvement there. So t...